Cancer: Orphan Drugs
Commons · Question 18871 · Tabled 14 Jul 2026 · Department of Health and Social Care · Official record
Answered 28 Sep 2026
Question
Asked by Scott Arthur
To ask the Secretary of State for Health and Social Care, whether the review of orphan medicines regulation required by the Rare Cancers Act 2026 will consider the full pathway from regulatory authorisation to NHS patient access, including evidence genera
Answer
Answered by James Frith, 28 Sep 2026
The review required by the Rare Cancers Act 2026 will focus on the regulatory framework for orphan medicines used in the diagnosis, prevention and treatment of rare cancers. It will consider international regulatory approaches and assess whether the Unite...